查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球細胞系開發市場 2023-2030
市場調查報告書
商品編碼
1380398

全球細胞系開發市場 2023-2030

Global Cell Line Development Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

預計全球細胞系開發市場在預測期內（2023-2030）將以 9.6% 的CAGR成長。細胞系開發是生物技術和藥物研究的關鍵過程，旨在創建穩定且高產量的細胞係以生產治療性蛋白質、抗體、疫苗和其他生物製藥。第一步涉及選擇合適的宿主細胞系，通常源自哺乳動物、昆蟲或微生物來源，這取決於產品的特定要求。

細分市場前景

全球細胞系開發市場按產品類型、來源類型、最終用戶和細胞系進行細分。根據產品類型，市場分為試劑和介質、設備和配件以及消耗品。根據來源類型，市場分為哺乳動物和非哺乳動物。根據最終用戶，市場細分為生物製藥和生物技術公司、合約研究組織以及學術和研究機構。根據細胞系，市場分為重組細胞、雜交瘤、連續細胞和原代細胞。在細胞系中，由於對治療癌症和自體免疫疾病的生物製劑的需求不斷成長，預計重組子細分市場將佔據相當大的市場佔有率。

預計哺乳動物細分市場將在全球細胞系開發市場中佔據相當大的佔有率

在來源類型中，哺乳動物細分市場預計將在全球細胞系開發市場中佔據相當大的佔有率。這種分段成長歸因於多種因素，例如哺乳動物細胞來源被用於生產單株抗體。這些細胞系產生複雜的蛋白質，讓人想起人體中的蛋白質，有助於創建定製藥物。此外，人體組織和其他生物成分可以輕鬆適應哺乳動物細胞系，進而降低感染風險。例如，2023 年6 月，Synthego 宣布與全球首屈一指的非營利生物材料和標準資源中心ATCC 建立突破性合作夥伴關係，為研究人員提供大量用於基因編輯應用的哺乳動物和小鼠細胞系，包括Express Cell池可提高獲得結果的速度。該聯盟匯集了其在基因組工程方面的專業知識以及 ATCC 作為經過驗證的生物材料和標準的值得信賴的提供者的聲譽。

區域展望

全球細胞系開發市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於醫療基礎設施的改善以及該地區政府的有利舉措，預計亞太地區將在全球市場中佔據顯著佔有率。

北美地區預計全球細胞系開發市場將以顯著的複合CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於醫療基礎設施的改善以及市場參與者為更好地研究和產品開發而增加的策略性舉措。例如，2023 年 9 月，Lineage Cell Therapeutics, Inc. 宣布根據該公司與 Eterna Therapeutics Inc. 的獨家選擇權和許可協議啟動某些開發活動，以產生新型低免疫誘導多能幹細胞 (iPSC) 系。這是2023 年2 月宣布的策略合作的下一步，根據該合作，Eterna 正在開發創新的工程低免疫iPSC 系，Lineage 將評估其分化為中樞神經系統(CNS) 疾病和其他神經病學適應症的細胞移植產品候選者的能力。自從早些時候宣布此項交易以來，Lineage 已與美國和國外領先的神經病學專家小組評估了其發展策略。經過這些和其他討論以及對競爭格局的評估，Lineage 最終確定了為 Eterna 開發的初始細胞系選擇特定基因編輯。這些編輯包括定向刪除 B2M 基因，旨在透過抑制 CD8+ T 細胞的排斥來降低源自該品系的候選產品的免疫原性； HLA-E 基因的標靶插入，旨在過度表達 HLA-E 並防止同種異體 NK 細胞反應，以及第三次未公開的編輯，旨在賦予臨床差異化和適用適應症的競爭優勢。 Lineage 預計這些編輯將擴大編輯細胞系的整體效用，包括非免疫特權或非人類白血球抗原 (HLA) 匹配的適應症，並將進一步將該細胞系與競爭對手目前使用的其他細胞系區分開來。

市場參與者展望

服務於細胞系開發市場的主要公司包括： Advanced Instruments、Berkeley Lights、Boehringer Ingelheim International GmbH、Creative BioLabs.、Danaher、Fujifilm Holdings Corp、Horizo​​​​n Discovery Ltd.、JSR Corp、Lonza、Merck KGaA Corning Inc.等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2019 年 4 月，細胞系開發 (CLD) 成像儀器生產商 Solentim 與生長促進非動物細胞培養試劑供應商 SAL Scientific 宣佈建立新的策略合作夥伴關係。此次合作將透過提供可顯著改善細胞生長的新型補充劑來進一步最佳化 CLD 工作流程。 Solentim 將擔任 SAL Scientific 'Insti' 產品系列的獨家經銷商。在化學成分明確、不含動物成分的培養基中生長的細胞可能容易受到生長和活力受損的影響，尤其是在受到壓力時。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 在全球細胞系開發市場營運的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Corning Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • GE Healthcare
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Thermo Fisher Scientific Inc
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按產品類型分類的全球細胞系開發市場
    • 試劑和介質
    • 裝置
    • 配件及消耗品
  • 按來源類型分類的全球細胞系開發市場
    • 哺乳動物
    • 非哺乳動物
  • 按最終用戶分類的全球細胞系開發市場
    • 生物製藥和生物技術公司
    • 學術界及研究機構
    • 合約研究組織
  • 按細胞系分類的全球細胞系開發市場
    • 重組
    • 雜交瘤
    • 連續的
    • 基本的

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Advanced Instruments
  • Berkeley Lights, Inc.
  • Boehringer Ingelheim International GmbH
  • Creative BioLabs.
  • Danaher Corp.
  • Fujifilm Holdings Corp
  • Horizon Discovery Ltd.
  • JSR Corp.
  • Lonza Group Ltd
  • Merck KGaA Corning Inc.
  • Rentschler Biopharma SE
  • Sartorius AG
  • Selexis SA
  • Sigma-Aldrich Corp
  • WuXi PharmaTech
Product Code: OMR2027859

Title: Global Cell Line Development Market Size, Share & Trends Analysis Report by Product Type (Reagent and Media, Equipment and Accessories and Consumables), by Source Type (Mammalian and Non-mammalian), by End User (Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes) and by Cell Line (Recombinant, Hybridomas, Continuous and Primary),Forecast Period (2023-2030).

The global Cell Line Development market is anticipated to grow at a CAGR of 9.6% during the Forecast Period (2023-2030). Cell line development is a critical process in biotechnology and pharmaceutical research, aimed at creating stable and high-yielding cell lines to produce therapeutic proteins, antibodies, vaccines, and other biopharmaceuticals. The initial step involves choosing a suitable host cell line, often derived from mammalian, insect, or microbial sources, depending on the specific requirements of the product.

Segmental Outlook

The global Cell Line Development market is segmented on the product type, Source type, End user, and cell line. Based on the product type, the market is sub-segmented into Reagent and Media, Equipment and Accessories and Consumables. Based on source type, the market is sub-segmented into Mammalian and Non-mammalian. Based on the end user, the market is sub-segmented into Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes. And based on cell line, the market is segmented into Recombinant, Hybridomas, Continuous and Primary. Among the cell line, the Recombinant sub-segment is anticipated to hold a considerable share of the market, owing to rising demand for biologics to treat cancer and autoimmune illnesses.

The Mammalian Sub-Segment is Anticipated to Hold a Considerable Share of the Global Cell Line Development Market

Among the Source Type, the Mammalian sub-segment is expected to hold a considerable share of the global Cell Line Development market. This segmental growth is attributed to several factors such as, mammalian cell sources are being used to create monoclonal antibodies. These cell lines produce intricate proteins that are reminiscent of those in the human body, aiding in the creation of customized medications. Additionally, human tissues and other biological components can easily adapt to mammalian cell lines, lowering the risk of infection. For instance, In June 2023, Synthego, announced a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results. This alliance brings together its expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards.

Regional Outlook

The global Cell Line Development market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to improving healthcare infrastructure, and favorable initiatives by government in the region.

The North America Region is Expected to Grow at a Significant CAGR in the Global Cell Line Development Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to improving medical infrastructure and increasing strategic initiatives by market players for better research and product development in the regions. For instance, in September 2023, Lineage Cell Therapeutics, Inc., announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company's exclusive option and license agreement with Eterna Therapeutics Inc. This marks the next step under the strategic collaboration announced in February 2023, under which Eterna is developing innovative engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system (CNS) diseases and other neurology indications. Since announcing the deal earlier, Lineage has evaluated its development strategy with a group of leading neurology experts in the US and abroad. As a result of these and other discussions, and an assessment of the competitive landscape, Lineage finalized its selection of specific gene edits for the initial cell lines to be developed by Eterna. The edits include the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells; the targeted insertion of the HLA-E gene, designed to overexpress HLA-E and prevent the allogeneic NK cell response, and a third undisclosed edit intended to confer clinical differentiation and a competitive advantage in the applicable indications. Lineage expects that these edits would expand the edited cell lines' overall utility, including for non-immune privileged or non-human leukocyte antigen (HLA) matched indications and will further differentiate the cell line from others currently in use by competitors.

Market Players Outlook

The major companies serving the Cell Line Development market include: Advanced Instruments, Berkeley Lights, Boehringer Ingelheim International GmbH, Creative BioLabs., Danaher, Fujifilm Holdings Corp, Horizon Discovery Ltd., JSR Corp, Lonza, Merck KGaA Corning Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2019, Solentim, the cell line development (CLD) imaging instrumentation producer, and SAL Scientific, a provider of growth-enhancing animal-free cell culture reagents, announced a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve cell growth. Solentim will act as the exclusive distributor for the SAL Scientific 'Insti' product range. Cells grown in chemically defined, animal component-free media can be susceptible to impaired growth and viability, especially when subjected to stress.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Cell Line Development market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Corning Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. GE Healthcare
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cell line development Market by Product Type
    • 4.1.1. Reagent and Media
    • 4.1.2. Equipment
    • 4.1.3. Accessories and Consumables
  • 4.2. Global Cell line development Market by Source Type
    • 4.2.1. Mammalian
    • 4.2.2. Non-mammalian
  • 4.3. Global Cell line development Market by End-User
    • 4.3.1. Biopharmaceutical and Biotechnology companies
    • 4.3.2. Academics and Research Institutes
    • 4.3.3. Contract Research Organizations
  • 4.4. Global Cell line development Market by Cell Line
    • 4.4.1. Recombinant
    • 4.4.2. Hybridomas
    • 4.4.3. Continuous
    • 4.4.4. Primary

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Instruments
  • 6.2. Berkeley Lights, Inc.
  • 6.3. Boehringer Ingelheim International GmbH
  • 6.4. Creative BioLabs.
  • 6.5. Danaher Corp.
  • 6.6. Fujifilm Holdings Corp
  • 6.7. Horizon Discovery Ltd.
  • 6.8. JSR Corp.
  • 6.9. Lonza Group Ltd
  • 6.10. Merck KGaA Corning Inc.
  • 6.11. Rentschler Biopharma SE
  • 6.12. Sartorius AG
  • 6.13. Selexis SA
  • 6.14. Sigma-Aldrich Corp
  • 6.15. WuXi PharmaTech

LIST OF TABLES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 13. GLOBAL RECOMBINANT CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY SOURCE TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY CELL LINES, 2022 VS 2030 (%)
  • 13. GLOBAL RECOMBINANT IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)